ReviewiLIVER2025
Emerging role of natural bioactive compounds in navigating the future of liver disease.
Review in iLIVER, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Understanding the role of hypoxia inducible factors in liver fibrosis and future therapeutic applications.iLIVER · 2026Review
- Tailored Porous Bimetallic Nanozyme Platform for Full-Cycle Therapeutics of Intestinal Ischemia/Reperfusion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Synergistic potential of natural products and exercise: unveiling molecular mechanisms and innovative therapeutic approaches for liver diseases.Frontiers in nutrition · 2025Review
- Nano-Enhanced Diets: Advancing Metabolic Dysfunction-Related Steatotic Liver Disease (MASLD) - A Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver diseases, including liver inflammation, fatty liver disease, cirrhosis, and hepatocellular carcinoma, represent significant global health challenges. Traditional treatments often emphasize symptom management, leading to increased interest in natural bioactive compounds for their potential therapeutic benefits. This review examines the role of natural bioactive compounds in managing hepatic disorders, with a particular focus on their mechanisms of action and supporting clinical evidence. Compounds such as curcumin, silymarin, resveratrol, triterpenoids, apigenin, and delphinidin derivatives have demonstrated promising hepatoprotective effects in preclinical studies, largely due to their anti-inflammatory, antioxidant, and anti-fibrotic properties. Nevertheless, further research is necessary to determine optimal dosing, safety profiles, and long-term effects. Understanding the mechanisms of action and therapeutic potential of these bioactive compounds may provide critical insights into their role in the treatment of hepatic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.